Language selection

Government of Canada / Gouvernement du Canada

Search

Infection prevention and control for COVID-19: Interim guidance for long-term care homes

Consider this guidance from December 23, 2021, in relation to Omicron: Interim COVID-19 infection prevention and control in the health care setting when COVID-19 is suspected or confirmed.

This document was was updated and re-posted on June 16, 2021. Please refer back for future updates.

Table of Contents

Changes in recent updates

The Public Health Agency of Canada (PHAC) develops evidence-informed infection prevention and control (IPC) guidance to complement provincial and territorial public health efforts in monitoring, preventing, and controlling healthcare-associated infections. Guidance will necessarily shift with the benefit of new scientific findings and their replication, as well as with thoughtful consideration of implications for practice in areas of uncertainty. National-level guidance should always be read in conjunction with relevant provincial, territorial and local policies and regulations.

February 26, 2021

PHAC is updating its interim guidance on infection prevention and control in long term-care homes (LTCHs) to consider emerging data on the transmission of SARS-CoV-2, the virus that causes COVID-19. While reports point to the occurrence of aerosol transmission in certain community circumstances (e.g., prolonged contact in closed indoor spaces with poor ventilation), there remains uncertainty around the exact role of aerosol transmission of SARS-CoV-2 and its impact in healthcare settings, including LTCHs.

PHAC will continue to consider new evidence as it becomes available. The following statements summarize the current knowledge used to inform updates to the guidance:

In this context, the following recommendations are being made in this guidance. LTCHs are also encouraged to refer to their provincial, territorial and local policies and regulations, which may vary depending on local epidemiology.

May 21, 2021 updates
PHAC is updating its interim guidance on infection prevention and control in LTCHs to consider the rollout of COVID-19 vaccines and emerging data on SARS-CoV-2 variants of concern.
PHAC will continue to consider new evidence as it becomes available. The following statements summarize the current knowledge used to inform updates to the guidance:

In this context, the following updated recommendations have been made in this guidance. LTCHs are also encouraged to refer to their provincial, territorial and local policies and regulations.
SARS-CoV-2 variants of concern:

Vaccination:

Individuals responsible for policy development, implementation and oversight of IPC measures at specific LTCHs should be familiar with relevant IPC background documents on Routine Practices and Additional Precautions and occupational health and safety (OHS) legislation. Facility IPC policies and procedures, protocols, guidance, education and training referred to within this document should be informed by IPC experts and regional and/or provincial/territorial directives or recommendations, and frequently reviewed and updated as needed. Wherever possible, these should be developed in conjunction with joint occupational health and safety committees (JOHSC) or workplace health and safety representatives. All LTCHs should have ongoing access to local IPC expertise, with at least one IPC-trained person assigned to manage COVID-19-related prevention and response activities in the LTCH.

Background

In December 2019, a cluster of cases of pneumonia of unknown origin was reported from Wuhan, Hubei Province in China. These cases were due to infection with a novel coronavirus, now called SARS-CoV-2, that causes a disease now referred to as COVID-19. A pandemic was declared by the World Health Organization on March 11, 2020.

For current information on the pandemic, please refer to the Public Health Agency of Canada Coronavirus Disease (COVID-19): Outbreak Update and to local, provincial or territorial public health authorities.

The purpose of this document is to provide updated interim IPC guidance to prevent the transmission of COVID-19 in Canadian homes/facilities for adults who require continuous supervised care, including professional health services, personal care and other services such as meals, laundry and housekeeping. These facilities may have different names, including but not limited to care homes/facilities, residential care homes/facilities, continuing care homes/facilities, personal care homes/facilities, nursing homes/facilities, centres d'hébergement et de soins de longue durée (CHSLDs), or other long-term care homes/facilities, hereafter all referred to as LTCHs. Some of the content may be adapted to other settings as appropriate (i.e., retirement homes).

This interim guidance is based upon experience with COVID-19 in Canada and other countries, as well as interim guidance from other international bodies. It has been informed by technical advice provided by members of the National Advisory Committee on Infection Prevention and Control (NAC-IPC). This guidance is informed by currently available scientific evidence and expert opinion, and is subject to change as new information becomes available.

The term "staff" is intended to include anyone working in LTCHs, including but not limited to those providing health care. The term "visitor" is intended to include anyone who is not employed directly by the LTCH but has been permitted entry into the facility, and includes but is not limited to volunteers, delivery personnel or contractors, outside care providers or consultants, family caregivers and general visitors.

Infection prevention and control preparedness

Each LTCH should be prepared to identify and manage residents who are considered exposed to, or suspected or confirmed to have COVID-19.

LTCH operators should ensure that:

All staff should ensure that:

LTCH staff safety and training

LTCHs should evaluate the potential risks posed to staff, and ensure that practices are in place to mitigate and manage them. 

Management of staff exposures

The LTCH's management, OHS professional(s), and infection prevention and control practitioner(s) should work collaboratively with public health authorities to manage staff exposed to COVID-19.

Access points

LTCHs should minimize access points and ensure that:

Screening and notification

Active screening should be conducted to promptly identify any individuals with signs and/or symptoms of COVID-19 or other respiratory illness.

Signs and symptoms of COVID-19 can vary from person to person. They may also vary according to age group (please see below Resident screening section for additional signs and symptoms reported in older adults).  Reported signs and symptoms include but are not limited to:

LTCHs should liaise with their local laboratories and acute care facilities to determine the most rapid way to have testing of staff and residents completed and reported.

All confirmed cases of COVID-19 are to be reported to the relevant jurisdictional public health authorities, and LTCHs should liaise with their affiliated laboratories for screening for variants of concern. Breakthrough cases of COVID-19 in vaccinated individuals should be reported to Public Health authorities.

Staff screening

Staff screening should include a twice daily self-assessment for exposures, signs and symptoms of COVID-19, including a temperature check.  Staff who develop any signs or symptoms of COVID-19 (of any severity) should:

Staff who have signs or symptoms of COVID-19, who have had recent unprotected exposure (as defined by facility, local, and jurisdictional public health or IPC guidance) to a person suspected or confirmed to have COVID-19, or who have been directed to self-isolate according to local public health directives, should not return to the LTCH until they have been cleared to do so according to local and jurisdictional public health guidance and facility IPC policies.

Designated staff should initiate and maintain a line listing of staff with suspected or confirmed COVID-19, as required by local, provincial or territorial public health guidelines, or as directed by facility occupational health and IPC policies.

Resident screening

Resident screening should include regular and thorough assessments for signs and symptoms of COVID-19. The frequency of assessment may vary by region and over time based on local COVID-19 epidemiology, but in areas with ongoing community transmission, assessments should occur at least daily.

Residents with signs or symptoms of COVID-19 should be placed immediately on a minimum of Droplet and Contact Precautions, and tested for COVID-19 as per local, provincial or territorial public health guidelines. Signs or symptoms of COVID-19 are listed above but considerations for older adults include:

Results of recent and serial resident assessments should be recorded and easily retrieved, in order to facilitate comparison and identification of changes in resident status.

Designated staff should initiate and maintain a line listing of residents with suspected or confirmed COVID-19, as required by local, provincial or territorial public health guidelines, or as directed by facility occupational health and IPC policies.

Visitor management

The term "visitor" is intended to include anyone who is not employed directly by the LTCH but has been permitted entry into the facility, and includes but is not limited to volunteers, delivery personnel or contractors, outside care providers or consultants, family caregivers and general visitors.

LTCHs should have visitor policies in place. Based on public health direction, outbreak status, or local or regional COVID-19 status, it may be necessary to restrict some visitation. Facilities should refer to local and jurisdictional public health guidance when establishing visitor policies; these should aim to balance the physical, psychological, emotional and spiritual needs of residents with the risk of introduction and transmission of COVID-19, and they may vary over time, depending on local COVID-19 epidemiology and vaccination coverage of staff and residents within facilities.

Visitors should:

Resident care and infection prevention and control measures

Routine practices

Routine Practices apply to all staff and residents, at all times, in all LTCHs, and include but are not limited to:

Point-of-care risk assessment

Prior to any resident interaction, all LTCH staff have a responsibility to assess the infectious risks posed to themselves, other staff, other residents and visitors from a resident, situation or procedure.

A PCRA includes determining if there may be:

Resident factors may include:

The selection and use of PPE during resident interactions should always be determined by the PCRA.

For interactions with residents who are considered exposed to, or suspected or confirmed to have COVID-19, PPE consistent with a minimum of Droplet and Contact Precautions (e.g., gloves, a gown, a medical mask and eye protection) should be worn. An N95 or equivalent respirator should be worn in place of a mask when performing or exposed to an AGMP. Use of an N95 or equivalent respirator may be considered in other circumstances under which risk of exposure to aerosolized virus may occur.

Hand hygiene

All LTCHs should have a hand hygiene program in place, with regular review and updating of staff education, training, and monitoring for adherence. LTCHs should make every effort to achieve 100 percent hand hygiene adherence. 

Staff should perform hand hygiene:

Hands may be cleaned using ABHR containing 60 to 90% alcohol, or plain liquid soap and water. Soap and water is preferable for use immediately after using toilet facilities, if hands are visibly soiled, and when caring for a resident with Clostridioides difficile infection.

Visitors are expected to perform hand hygiene under the same circumstances outlined above for staff and should be trained on how to do so properly.

Residents should also be taught how to perform proper hand hygiene, and assisted with this if they have physical or cognitive limitations. Residents should perform hand hygiene:

Personal protective equipment

All PPE (e.g., gloves, gowns, medical masks, N95 or equivalent respirators, eye protection) should be supplied in adequate amounts and sizes in all resident care areas, and placed so it is readily accessible at the point-of-care for all staff and visitors. Additional supplies of PPE should be stored in clean supply rooms that are clearly separated from any soiled utility areas.

Training should be provided, with posters clearly outlining the steps for putting on and removing PPE posted for visual cues inside and outside each room of a resident who is considered exposed to, or suspected or confirmed to have COVID-19.

All staff using PPE should:

Masking and eye protection for the full duration of shifts or visits

Given ongoing community spread of COVID-19 within Canada and evidence that transmission occurs from those who have few or no symptoms, masking for the full duration of shifts or visits for all LTCH staff and visitors is recommended. The rationale for full-shift masking of LTCH staff and visitors is to reduce the risk of transmitting COVID-19 infection from staff or visitors to others, at a time when no symptoms of illness are recognized, but the virus can be transmitted. Staff should support visitors to ensure appropriate use of medical masks.

Use of eye protection (e.g., a face shield) for the full duration of staff shifts is also recommended in LTCHs, based on local epidemiology. This applies to all staff working in resident care areas. Eye protection is also recommended for visitors in close proximity to residents in a LTCH that is experiencing an outbreak.

LTCHs should refer to facility IPC and provincial and territorial guidance on specific recommendations for use of medical masks, eye protection and other PPE, as well as PPE conservation strategies.  When medical masks and eye protection are recommended for the full duration of shifts or visits, staff and visitors should:

When an N95 or equivalent respirator is deemed necessary based on the staff PCRA, staff should follow facility procedures for taking off a medical mask (and eye protection, if worn), and then put on a fit-tested N95 or equivalent respirator and replace their eye protection, with meticulous hand hygiene performed at all steps.

Masks worn as source control, and eye protection worn for the duration of shifts (i.e., not when used for encounters with residents on Additional Precautions), may be worn for extended periods.  Any extended use policies should be developed with IPC expert consultation or guidance. Masks or N95 or equivalent respirators and eye protection should be replaced when they become damaged, wet, damp, or soiled (from the wearer's breathing or external splash), or when they come in direct contact with a resident.  Staff should be informed of how to access additional masks or N95 or equivalent respirators and eye protection when needed.

Additional precautions

A minimum of Droplet and Contact Precautions should be implemented for all residents who are considered exposed to, diagnosed with, or who have signs or symptoms of possible COVID-19.

Aerosol-generating medical procedures

Some medical procedures have been reported to increase the likelihood of generating infectious aerosols, and linked to transmission of other respiratory viruses. These are often referred to as aerosol-generating procedures (AGPs) or aerosol-generating medical procedures (AGMPs). There are many knowledge gaps as to which procedures pose the greatest risk of aerosol generation and transmission of SARS-CoV-2. It is likely that the degree of risk may also vary depending on the resident, the operator, and the setting. Most procedures that are reported to pose increased risk of aerosol generation and transmission of respiratory viruses are rarely performed in LTCHs, though potential examples in this setting may include open endotracheal suctioning in residents who have a tracheostomy, or use of non-invasive positive-pressure ventilation (e.g., continuous positive airway pressure or CPAP) machines.

Guidance for procedures that require the use of an N95 or equivalent respirator should be followed. This guidance may vary among provinces and territories.

AGMPs are ideally performed in AIIRs if these are available. If a resident requires an AGMP, the resident should at minimum be placed in a private room with the door closed.

AGMPs on a resident who is considered potentially infectious with SARS-CoV-2 should only be performed when all staff in the room are wearing a fit-tested, seal-checked N95 or equivalent respirator, gloves, a gown and eye protection.

In addition:

Resident placement and accommodation

The following are important considerations for resident placement and accommodation:

Resident activity

IPC practices to prevent introduction and transmission of COVID-19 into and within LTCHs during resident activity should include:

Residents who are considered exposed to, or suspected or confirmed to have COVID-19 should stay in their room until they have met the criteria for discontinuation of Additional Precautions in accordance with facility IPC protocols and provincial and territorial public health guidance. Those undergoing CPAP or Bilevel Positive Airway Pressure (BiPAP) should not be moved. Movement or transfer within and between facilities of residents who are suspected to be infectious should be avoided unless medically necessary.

If residents who are considered exposed to or suspected or confirmed to have COVID-19 must leave their room for medically necessary care or treatment, they should:

A minimum of Droplet and Contact Precautions should be maintained by staff during resident transport, and communicated along with relevant clinical information to the transferring service and receiving unit ahead of transfer.

Wheelchairs or transport stretchers should be cleaned and disinfected prior to exiting the resident's room and after being used.  Any surfaces outside the room that the resident may have touched should be cleaned and disinfected.

Outbreak management

A single confirmed case of COVID-19 is justification to suspect a potential outbreak in a LTCH. Testing of staff and residents, and application of outbreak measures to a unit or facility, should involve detailed consideration for the LTCH layout and potential transmission routes between units, e.g., staff cross-coverage or shared communal spaces. LTCHs should refer to local and jurisdictional public health and IPC authorities for specific definitions and directives on case reporting and outbreak management.

When an outbreak occurs in a facility, an emergency operations team should be established; this should involve the LTCH administrators/directors, local and regional public health and administration, IPC practitioners, and other external supports for resident and staff testing, PPE acquisition, personnel/staffing, and communications as needed.

Once COVID-19 has been confirmed in a LTCH:

Outbreak management strategies may include but are not limited to:

Discontinuing additional precautions

The duration and discontinuation of Additional Precautions for an individual resident or unit (where precautions may be universally applied during a COVID-19 outbreak) should be determined on a case-by-case basis, in consultation with IPC expertise and in accordance with local, provincial and territorial public health guidance.

The duration of Additional Precautions for a symptomatic resident with COVID-19 should be a minimum of 10 days from onset of symptoms (and a minimum of 10 days from the first positive test for residents who remain asymptomatic), and may be longer depending upon the duration of symptoms, disease severity and the presence of underlying immunocompromising conditions.

Handling bodies of deceased persons

Routine Practices should be used properly and consistently when handling the bodies of people who are deceased, including preparing bodies for autopsy or transfer to mortuary services. Federal guidance is available, and provincial and territorial communicable disease regulations should be followed.

Handling laboratory specimens

All specimens collected for laboratory investigations should be regarded as potentially infectious. Clinical specimens should be collected and transported in accordance with organizational policies and procedures. For proper laboratory biosafety procedures when handling samples from residents under investigation for COVID-19, refer to the PHAC's biosafety advisory.

Handling resident care equipment

All reusable equipment and supplies, electronics, personal belongings, etc., should be dedicated to the use of the resident who is considered exposed to, or suspected or confirmed to have COVID-19. If reuse with other residents is necessary, the equipment and supplies should first be cleaned and disinfected with a hospital-grade disinfectant for the recommended contact time. Items that have been cleaned and disinfected should be clearly identified as such (e.g., with tags) and stored separately from any non-clean and non-disinfected items.

Single-use disposable equipment should be discarded into a no-touch waste receptacle immediately after use.

Upon resident discharge, items that cannot be appropriately cleaned and disinfected should be discarded. Resident-owned items with hard surfaces should be cleaned and disinfected, and all items placed in a bag for family or a representative to take. Resident items and laundry should be handled with gloves and then cleaned and disinfected or laundered with regular laundry soap and hot water (60-90°C) followed by handwashing and prior to subsequent use. Unwanted items should be discarded.

Environmental cleaning and disinfection

Cleaning and disinfection of high-touch surfaces is important for controlling the spread of microorganisms. Environmental disinfectants should be classified as hospital disinfectants, registered in Canada with a Drug Identification Number (DIN), and labelled as effective for both enveloped and non-enveloped viruses. Manufacturer's instructions for use and required contact times should be followed to ensure adequate disinfection. If commercially-prepared hospital-grade disinfectants are not available, LTCHs may use a diluted bleach solution to disinfect the environment. The concentration of chlorine should be 1,000 ppm or 0.1% (equivalent to a 1:50 dilution of 5% concentrated liquid bleach). When using bleach, cleaning must precede disinfection.

All resident room surfaces that are considered "high-touch" (e.g., telephone, bedside table, overbed table, chair arms, call bell cords or buttons, door handles, light switches, bedrails, handwashing sink, bathroom sink, toilet and toilet handles, shower handles, faucets or shower chairs, grab bars, outside of paper towel dispenser) should be cleaned and disinfected at least daily and when soiled. Hospital-grade disinfectant (e.g., disinfectant wipes) should be used with the recommended contact time to disinfect smaller resident care equipment (e.g., blood pressure cuffs, electronic thermometers, pulse oximeters, stethoscopes) after each use. Room cleaning and disinfection of low-touch surfaces (e.g., shelves, bedside chairs or benches, windowsills, headwall units, overbed light fixtures, message or white boards, outside of sharps containers) should also be performed on a regular basis and when soiled. Floors and walls should be kept visibly clean and free of spills, dust and debris.

All surfaces or items outside of the resident room that are touched by or in contact with staff (e.g., computer carts, medication carts, charting desks or tables, computer screens, telephones, touch screens, chair arms) should be cleaned and disinfected at least daily and when soiled. Staff should ensure that their hands are clean before touching the above-mentioned equipment.

In rooms of residents who are considered exposed to, or suspected or confirmed to have COVID-19, shared staff or resident common spaces, and in cases of outbreaks, more frequent cleaning and disinfection is required.

Environmental services staff should wear the same PPE as other staff when cleaning and disinfecting the resident room.

The facility's protocol for cleaning of the resident's room after discharge, transfer, or discontinuation of Droplet and Contact Precautions should be followed. Toilet brushes, unused toilet paper and other disposable supplies should be discarded, and all bedside privacy curtains removed and laundered at the time of resident discharge or transfer.

Linen, dishes and cutlery

Routine Practices should be used.

Waste management

Routine Practices should be used.

Monitoring and evaluation

LTCHs should ensure that processes to monitor processes and outcomes related to managing residents with suspected or confirmed COVID-19 are in place. These may include:

Bibliography

Ahmad, J., Anwar, S., Latif, A., Haq, N. U., Sharif, M., & Nauman, A. A. (2020). The Association of PPE Availability, Training and Practices with COVID-19 Sero-prevalence in Nurses and Paramedics in Tertiary Care Hospitals of Peshawar, Pakistan. Disaster Med Public Health Prep, 1-18. doi:10.1017/dmp.2020.438

Airborne Transmission of SARS-CoV-2 - Proceedings of a Workshop. Retrieved from https://www.nap.edu/read/25958/chapter/1

Alajmi, J., Jeremijenko, A. M., Abraham, J. C., Alishaq, M., Concepcion, E. G., Butt, A. A., & Abou-Samra, A.-B. (2020). COVID-19 infection among healthcare workers in a national healthcare system: The Qatar experience. Int J of Infect Dis, 100, 386-389. doi:10.1016/j.ijid.2020.09.027

Alberta Health Services. (2020, June 12). Topic: Effectiveness of screening programs for reducing the spread of COVID-19 in healthcare settings. Retrieved from: https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-effectiveness-of-workplace-screening-programs-rapid-review.pdf

Alberta Health Services. (2020, June 5). Has there been documented transmission of SARS-Cov-2 virus (or similar viruses) through heating, ventilation, and air conditioning (HVAC) systems in hospitals or nonhospital settings?  Retrieved from: https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-risk-transmission-hvac-systems-rapid-review.pdf

Alkurt, G., Murt, A., Aydin, Z., Tatli, O., Agaoglu, N. B., Irvem, A., . . . Doganay, L. (2020). Seroprevalence of coronavirus disease 2019 (COVID-19) among health care workers from three pandemic hospitals of Turkey. Preprint medRxiv doi:10.1101/2020.08.19.20178095

Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., . . . Rappuoli, R. (2020). SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. Preprint bioRxiv. doi:10.1101/2020.12.28.424451

Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y., & Leshem, E. (2021). Early rate reductions of SARS-CoV 2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet, 397(10277), 875-877. doi:10.1016/S0140-6736(21)00448-7

Asadi, S., Wexler, A. S., Cappa, C. D., Barreda, S., Bouvier, N. M., & Ristenpart, W. D. (2019). Aerosol emission and superemission during human speech increase with voice loudness. Sci Rep, 9(1), 2348. doi:10.1038/s41598-019-38808-z

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., . . . Group, C. S. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 384(5), 403-416. doi:10.1056/NEJMoa2035389

Bae, S., Kim, H., Jung, T. Y., Lim, J. A., Jo, D. H., Kang, G. S., . . . Kwon, H. J. (2020). Epidemiological Characteristics of COVID-19 Outbreak at Fitness Centers in Cheonan, Korea. J Korean Med Sci, 35(31), e288. doi:10.3346/jkms.2020.35.e288

Bartoszko, J. J., Farooqi, M. A. M., Alhazzani, W., & Loeb, M. (2020). Medical masks vs N95 respirators for preventing COVID-19 in healthcare workers: A systematic review and meta-analysis of randomized trials. Influenza Other Respir Viruses, 14(4), 365-373. doi:10.1111/irv.12745

Bourouiba, L. (2020). Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19. JAMA, 323(18), 1837-1838. doi:10.1001/jama.2020.4756

Cai, J., Sun, W., Huang, J., Gamber, M., Wu, J., & He, G. (2020). Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020. Emerg Infect Dis, 26(6), 1343-1345. doi:10.3201/eid2606.200412

Calò, F., Russo, A., Camaioni, C., De Pascalis, S., & Coppola, N. (2020). Burden, risk assessment, surveillance and management of SARS-CoV-2 infection in health workers: A scoping review. Infect Dis Poverty, 9 (1), 139. doi:10.1186/s40249-020-00756-6

Cao, G., Tang, S., Yang, D., Shi, W., Wang, X., Wang, H., . . . Ma, L. (2020). The potential transmission of SARS-CoV-2 from patients with negative RT-PCR swab tests to others: two related clusters of COVID-19 outbreak. Jpn J Infect Dis, 73(6), 399-403. doi:10.7883/yoken.JJID.2020.165

Carretta, G., Contessa, C., Boemo, D. G., Bordignon, G., Bennici, S. E., Merigliano, S., . . . Donato, D. (2020). COVID-19 challenge: Proactive management of a tertiary university hospital in Veneto region, Italy. Pathog Glob Health, 114(6), 309-317. doi:10.1080/20477724.2020.1806614

Cattelan, A. M., Sasset, L., Di Meco, E., Cocchio, S., Barbaro, F., Cavinato, S., . .Baldo, V. (2020). An integrated strategy for the prevention of SARS-CoV-2 infection in healthcare workers: A prospective observational study. Int J Environ Res Public Health 17(16). doi:10.3390/ijerph17165785

Cele, S., Gazy, I., Jackson, L., Hwa, S. H., Tegally, H., Lustig, G., . . . Sigal, A. (2021). Escape of SARS CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. doi:10.1038/s41586-021-03471-w

Centers for Disease Control and Prevention: Cluster of severe acute respiratory syndrome cases among protected health care workers - Toronto, April 2003. MMWR Morb Mortal Wkly Rep 2003; 52:433–436

Centers for Disease Control and Prevention. (2020). Considerations for Memory Care Units in Long-Term Care Facilities.   Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/hcp/memory-care.html

Centers for Disease Control and Prevention. (2020). Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings (Interim Guidance).   Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html

Centers for Disease Control and Prevention. (2020). Duration of Isolation and Precautions for Adults with COVID-19.  Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html

Centers for Disease Control and Prevention. (2020). Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic.   Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html

Centers for Disease Control and Prevention. (2020). Preparing for COVID-19 in Nursing Homes.   Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html

Centers for Disease Control and Prevention. (2020). Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission.   Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-sars-cov-2.html

Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., . . . Diamond, M. S. (2021). Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. doi:10.1038/s41591-021-01294-w

Cheng, V. C., Wong, S. C., Chan, V. W., So, S. Y., Chen, J. H., Yip, C. C., . . . Yuen, K. Y. (2020). Air and environmental sampling for SARS-CoV-2 around hospitalized patients with coronavirus disease 2019 (COVID-19). Infect Control Hosp Epidemiol, 41(11), 1258-1265. doi:10.1017/ice.2020.282

Chodick, G., Tene, L., Gazit, S., Ben Tov A., Cohen, D., & Muhsen, K. The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence. Preprint medRxiv. doi:10.1101/2021.01.27.21250612

Chou, R., Dana, T., Buckley, D. I., Selph, S., Fu, R., & Totten, A. M. (2020). Update Alert 5: Epidemiology of and risk factors for coronavirus infection in health care workers: A living rapid review. Ann Intern Med, 173(2), 120-136. doi:10.7326/M20-1632

CIHR-PHAC-CADTH – Best Brains Exchange – Transmission Routes for COVID-19: Implications for Public Health. (2020).   Retrieved from https://cihr-irsc.gc.ca/e/52238.html

Collier, D. A., De Marco, A., Ferreira, I., Meng, B., Datir, R., Walls, A. C., . . . Gupta, R. K. (2021). SARS CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. medRxiv. doi:10.1101/2021.01.19.21249840

Contejean, A., Leporrier, J., Canoui, E., Alby-Laurent, F., Lafont, E., Beaudeau, L., Kerneis, S. (2020). Comparing dynamics and determinants of SARS-CoV-2 transmissions among health care workers of adult and pediatric settings in central Paris. Clin Infect Dis. doi:10.1093/cid/ciaa977 Epub ahead of print.

Da Silva Francisco Jr., R., Benites, L. F., Lamarca, A. P., de Almeida, L. G. P., Hansen, A. W., Gularte, J. S., . . . Spilki, F. R. (2021). Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil. Virus Res, 296, 198345. doi:10.1016/j.virusres.2021.198345

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., . . . Balicer, R. D. (2021). BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. doi:10.1056/NEJMoa2101765

Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., . . . Crotty, S. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science, 371(6529). doi:10.1126/science.abf4063

Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., . . . Edmunds, W. J. (2021). Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science, 372(6538). doi:10.1126/science.abg3055

Davies, N. G., Jarvis, C. I., Group, C. C.-W., Edmunds, W. J., Jewell, N. P., Diaz-Ordaz, K., & Keogh, R. H. (2021). Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. doi:10.1038/s41586-021-03426-1

Diamond, M., Chen, R., Xie, X., Case, J., Zhang, X., VanBlargan, L., . . . Gilchuk, P. (2021). SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Res Sq. doi:10.21203/rs.3.rs-228079/v1

ECDC. (2021, April 8, 2021). Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA.   Retrieved from https://www.ecdc.europa.eu/sites/default/files/documents/Reinfection-with-SARSCoV2-implementation-of-a-surveillance-case-definition.pdf

Edara, V. V., Floyd, K., Lai, L., Gardner, M., Hudson, W., Piantadosi, A., . . . Suthar, M. S. (2021). Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. medRxiv. doi:10.1101/2021.02.02.21250799

Eguia, E., Crawford, K. H. D., Stevens-Ayers, T., Kelnhofer-Millevolte, L., Greninger, A. L., Englund, J. A., . . . Bloom, E. D. A human coronavirus evolves antigenically to escape antibody immunity. Preprint bioRxiv

Erber, J., Kappler,  V.,  Haller, B., Mijočević, H., Galhoz, A., da Costa, C. P., . . . Lingor, P. (2020). Strategies for infection control and prevalence of anti-SARS-CoV-2 IgG in 4,554 employees of a university hospital in Munich, Germany. Preprint medRxiv doi:10.1101/2020.10.04.20206136

European Centre for Disease Control and Prevention. (2020). Guidance for discharge and ending of isolation of people with COVID-19.   Retrieved from https://www.ecdc.europa.eu/sites/default/files/documents/Guidance-for-discharge-and-ending-of-isolation-of-people-with-COVID-19.pdf

European Centre for Disease Control and Prevention. (2020). Infection prevention and control and preparedness for COVID-19 in healthcare settings.   Retrieved from https://www.ecdc.europa.eu/sites/default/files/documents/Infection-prevention-and-control-in-healthcare-settings-COVID-19_5th_update.pdf

Evans, S., Agnew, E., Vynnycky, E., & Robotham, J. V. (2020). The impact of testing and infection prevention and control strategies on within-hospital transmission dynamics of covid-19 in English hospitals. Preprint medRxiv doi:10.1101/2020.05.12.20095562

Fears, A. C., Klimstra, W. B., Duprex, P., Hartman, A., Weaver, S. C., Plante, K. S., . . . Roy, C. J. (2020). Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions. Emerg Infect Dis, 26(9). doi:10.3201/eid2609.201806

Focosi, D., & Maggi, F. (2021). Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. doi:10.1002/rmv.2231

Frampton, D., Rampling, T., Cross, A., Bailey, H., Heaney, J., Byott, M., & Nastouli, E. (2021). Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole genome sequencing and hospital-based cohort study. The Lancet Infectious Diseases

Galanis, P., Vraka, I., Fragkou, D., Bilali, A., & Kaitelidou, D. (2020). Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Health Care Workers: A Systematic Review and Meta-Analysis. J Hosp Infect. doi:10.1016/j.jhin.2020.11.008 Epub ahead of print

Garcia-Beltran, W. F., Lam, E. C., St Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., . . . Balazs, A. B. (2021). Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. doi:10.1016/j.cell.2021.03.013

Garzaro, G., Clari, M., Ciocan, C., Grillo, E., Mansour, I., Godono, A., . . . Pira, E. (2020). COVID-19 infection and diffusion among the healthcare workforce in a large university-hospital in northwest Italy. Med Lav, 111(3), 184-194. doi:10.23749/mdl.v111i3.9767

Gmehlin, C. G., & Munoz-Price, L. S. (2020). Coronavirus disease 2019 (COVID-19) in long-term care facilities: A review of epidemiology, clinical presentations, and containment interventions. Infect Control Hosp Epidemiol, 1-6. doi:10.1017/ice.2020.1292

Golubchik, T., Lythgoe, K. A., Hall, M., Ferretti, L., Fryer, H. R., MacIntyre-Cockett, M., & Todd, J. A. (2021). Early analysis of a potential link between viral load and the N501Y mutation in the SARS-COV2 spike protein. Preprint medRxiv. doi:10.1101/2021.01.12.20249080

Gomez-Ochoa, S., Franco, O. H., Rojas, L. Z., … Muka, T. (2020). COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes. Am J Epidemiol. doi:10.1093/aje/kwaa191 Epub ahead of print.

Graham, M. S., Sudre, C. H., Anna May, M. A., Antonelli, M., Murray, B., Varavsky, T., & Ourselin, S. (2021). Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. The Lancet Public Health. doi:doi.org/10.1016/S24682667(21)00055-4

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021). Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe, 29(3), 463-476 e466. doi:10.1016/j.chom.2021.02.003

Guo, X., Wang, J., Hu, D., Wu, L., Gu, L., Wang, Y., . . . Wu, Y. (2020). Survey of COVID-19 disease among orthopaedic surgeons in Wuhan, People's Republic of China. J Bone Joint Surg Am, 102(10), 847-854. doi:10.2106/JBJS.20.00417

Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., . . . Hopkins, S. (2021). Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). Prerint SSRN. doi:10.2139/ssrn.3790399

Hamner, L., Dubbel, P., Capron, I., Ross, A., Jordan, A., Lee, J., . . . Leibrand, H. (2020). High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020. MMWR Morb Mortal Wkly Rep, 69(19), 606-610. doi:10.15585/mmwr.mm6919e6

Harrington, D., Kele, B., Pereira, S., Couto-Parada, X., Riddell, A., Forbes, S., . . . Cutino-Moguel, T. (2021). Confirmed Reinfection with SARS-CoV-2 Variant VOC-202012/01. Clin Infect Dis. doi:10.1093/cid/ciab014

Hatfield, K. M., Reddy, S. C., Forsberg, K., Korhonen, L., Garner, K., Gulley, T., . . .Jernigan, J. A. (2020). Facility-Wide Testing for SARS-CoV-2 in Nursing Homes –Seven U.S. Jurisdictions, March-June 2020. MMWR Morb Mortal Wkly Rep, 69(32), 1095-1099. doi:10.15585/mmwr.mm6932e5

Hawkins, E. S., Fertel, B. S., Muir, M. R., Meldon, S. W., Delgado, F. J., & Smalley, C. M. (2020). Adding eye protection to universal masking reduces covid-19 among frontline emergency clinicians to the level of community spread. Am J Emerg Med. doi:10.1016/j.ajem.2020.08.064 Epub ahead of print.

High, K. P., Bradley, S. F., Gravenstein, S., Mehr, D. R., Quagliarello, V. J., Richards, C., & Yoshikawa, T. T. (2009). Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis, 48(2), 149-171. doi:10.1086/595683

Hoffman, M., Arora, P., GroB, R., Seidel, A., NHornich, B., Hahn, A., & Pohlmann, S. (2021). SARS-CoV2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination. Preprint bioRxiv. doi:10.1101/2021.02.11.430787

Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., 3rd, . . . Baric, R. S. (2020). SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science, 370(6523), 1464-1468. doi:10.1126/science.abe8499

Huang, Q., Mondal, A., Jiang, X., Horn, M. A., Fan, F., Fu, P., . . . Gurarie, D. (2020). SARS-CoV-2 transmission and control in a hospital setting: An individual-based modelling study. Preprint medRxiv doi:10.1101/2020.08.22.20179929

Hyams, C., Marlow, R., Maseko, Z., Ward, L., Fox, K., & Finn, A. (2021). Assessing the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study. Preprint SSRN. doi:10.2139/ssrn.3796835

Huang, Z., Zhao, S., Li, Z., Chen, W., Zhao, L., Deng, L., & Song, B. (2020). The battle against coronavirus disease 2019 (COVID-19): Emergency management and infection control in a radiology department. J Am Coll Radiol, 17(6), 710-716. doi:10.1016/j.jacr.2020.03.011

ICEG. (2020). COVID-19 Guidance on the use of personal protective equipment by health care workers in areas with significant community transmission.   Retrieved from https://www.health.gov.au/sites/default/files/documents/2020/08/coronavirus-covid-19-guidance-on-the-use-of-personal-protective-equipment-by-health-care-workers-in-areas-with-significant-community-transmission-coronavirus-covid-19-guidance-on-the-use-of-personal-protective-equipment-by_0.pdf

ICEG. (2020). COVID-19 Infection Prevention and Control for Residential Care Facilities.   Retrieved from https://www.health.gov.au/sites/default/files/documents/2020/09/coronavirus-covid-19-guidelines-for-infection-prevention-and-control-in-residential-care-facilities.pdf

ICEG. (2021, April 14, 2021). New variants of SARS-CoV-2 and implications for infection prevention and control practices. A statement from the Infection Control Expert Group (ICEG) on transmission of SARS-CoV-2.   Retrieved from https://www.health.gov.au/news/new-variants-of-sars-cov-2-and implications-for-infection-prevention-and-control-practices

Jang, S., Han, S. H., & Rhee, J. Y. (2020). Cluster of Coronavirus Disease Associated with Fitness Dance Classes, South Korea. Emerg Infect Dis, 26(8), 1917-1920. doi:10.3201/eid2608.200633

Jespersen, S., Mikkelsen, S., Greve, T., Kaspersen, K. A., Tolstrup, M., Boldsen, J. K., . . . Erikstrup, C. (2020). SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the central Denmark region. Clin Infect Dis. doi:10.1093/cid/ciaa1471 Epub ahead of print.

Jiaqiang, Z., Mingyang, S., Weijia, Z., Ningtao, L., MingZhang, Z., Lei, Q., & Szu-Yuan, W. (2020). Predictive factors of transmission during endotracheal intubation for coronavirus disease 2019 (COVID-19). Preprint SSRN doi:10.22139/ssrn.3557990

Jin, Y.H., Huang, Q., Wang, Y.Y., Zeng, X.T., Luo, L.S., Pan, Z.Y., . . . Wang, X.-H. (2020). Perceived infection transmission routes, infection control practices, psychosocial changes, and management of COVID-19 infected healthcare workers in a tertiary acute care hospital in Wuhan: A cross-sectional survey. Mil Med Res, 7(1), 24. doi:10.1186/s40779-020-00254-8

Jones, C. R., Hamilton, F. W., Thompson, A., Morris, T. T., & Moran, E. (2020). Seroprevalence of SARS-CoV-2 IgG in healthcare workers and other staff at North Bristol NHS Trust: A sociodemographic analysis. J Infect. doi:10.1016/j.jinf.2020.11.036 Epub ahead of print

Kidd, M., Richter, A., Best, A., Cumley, N., Mirza, J., Percival, B., . . . McNally, A. (2021). S-variant SARS CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR. J Infect Dis. doi:10.1093/infdis/jiab082

Kim, S. W., Jo, S. J., Lee, H., Oh, J. H., Lim, J., Lee, S. H., . . . Lee, J. (2020). Containment of a healthcare-associated covid-19 outbreak in a university hospital in Seoul, Korea: A single-center experience. PLoS One.  15(8), e0237692. doi:10.1371/journal.pone.0237692 Epub ahead of print.

Kimball, A., Hatfield, K. M., Arons, M., James, A., Taylor, J., Spicer, K., . . . Team, C. C.-I. (2020). Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep, 69(13), 377-381. doi:10.15585/mmwr.mm6913e1

King, M.F., Wilson, A. M., Weir, M. H., Lopez-Garcia, M., Proctor, J., . . . Noakes, C. J. (2020). Modelling the risk of SARS-CoV-2 infection through PPE doffing in a hospital environment. Preprint medRxiv doi:10.1101/2020.09.20.20197368

Knoll, R. L., Klopp, J., Bonewitz, G., Grondahl, B., Hilbert, K., Kohnen, W., . . . Gehring, S. (2020). Containment of a large SARS-CoV-2 outbreak among healthcare workers in a pediatric intensive care unit. Pediatr Infect Dis J, 39(11), e336-e339. doi:10.1097/INF.0000000000002866

Koh, W. C., Naing, L., Chaw, L., Rosledzana, M. A., Alikhan, M. F., Jamaludin, S. A., . .. Wong, J. (2020). What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors. PLoS One, 15(10), e0240205-e0240205. doi:10.1371/journal.pone.0240205

Laffeber, C., de Koning, K., Kanaar, R., & Lebbink, E. H. G. (2021). Experimental evidence for enhanced receptor binding by rapidly spreading SARS-CoV-2 variants. Preprint bioRxiv. doi:10.1101/2021.02.22.432357

Lai, X., Wang, M., Qin, C., Tan, L., Ran, L., Chen, D., . . . Wang, W. (2020). Coronavirus disease 2019 (COVID-2019) infection among health care workers and implications for prevention measures in a tertiary hospital in Wuhan, China. JAMA Netw Open, 3(5), e209666. doi:10.1001/jamanetworkopen.2020.9666

Lednicky, J. A., Lauzardo, M., Fan, Z. H., Jutla, A., Tilly, T. B., Gangwar, M., . . . Wu, C. Y. (2020). Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. Int J Infect Dis, 100, 476-482. doi:10.1016/j.ijid.2020.09.025

Lee, S., Kim, T., Lee, E., Lee, C., Kim, H., Rhee, H., . . . Kim, T. H. (2020). Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. JAMA Intern Med. doi:10.1001/jamainternmed.2020.3862

Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., & Wu, J. T. (2021). Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill, 26(1). doi:10.2807/1560-7917.ES.2020.26.1.2002106

Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., . . . Wang, Y. (2021). SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. doi:10.1016/j.cell.2021.02.042

Licina, A., Silvers, A. J., & Stuart, R. (2020). Use of powered air-purifying respirator(papr) by healthcare workers for preventing highly infectious viral diseases -a systematic review of evidence. Syst Rev, 9(1), 173. doi:10.1186/s13643-020-01431-5

Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., . . . Shi, P. Y. (2021). Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med. doi:10.1056/NEJMc2102017

Liu, Y., Ning, Z., Chen, Y., Guo, M., Liu, Y., Gali, N. K., . . . Lan, K. (2020). Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature, 582(7813), 557-560. doi:10.1038/s41586-020-2271-3

Lu, J., & Yang, Z. (2020). COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020. Emerg Infect Dis, 26(11), 2791-2793. doi:10.3201/eid2611.203774

Lu, J., Gu, J., Li, K., Xu, C., Su, W., Lai, Z., . . . Yang, Z. (2020). COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020. Emerg Infect Dis, 26(7), 1628-1631. doi:10.3201/eid2607.200764

Luong-Nguyen, M., Hermand, H., Abdalla, S., Cabrit, N., Hobeika, C., Brouquet, A., . . . Sauvanet, A. (2020). Nosocomial infection with SARS-CoV-2 within departments of digestive surgery. J Visc Surg, 157(3S1), S13-S18. doi:10.1016/j.jviscsurg.2020.04.016

Luqman Arafath, T. K., Jubbal, S. S., Gireesh, E. D., Margapuri, J., Jogu, H. R., . . . Penupolu, S. (2020). Risk of transmission of infection to healthcare workers delivering supportive care for coronavirus pneumonia; a rapid GRADE review. Preprint medRxiv doi:10.1101/2020.07.06.20146712

Lynch, J. B., Davitkov, P., Anderson, D. J., Bhimraj, A., Cheng, V. C., Guzman-Cottrill, J., . . . Sultan, S. (2020). Infectious Diseases Society of America Guidelines on Infection Prevention for Health Care Personnel Caring for Patients with Suspected or Known COVID-19. Clin Infect Dis. doi:10.1093/cid/ciaa1063

Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., . . . Group, N.-S. G. W.-V. C. (2021). Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. doi:10.1056/NEJMoa2102214

Mandić-Rajčević, S., Masci, F., Crespi, E., Franchetti, S., Longo, A., Bollina, I., . . . Colosio, C. (2020). Contact tracing and isolation of asymptomatic spreaders to successfully control the COVID-19 epidemic among healthcare workers in Milan (Italy). Preprint medRxiv doi:10.1101/2020.05.03.20082818

McMichael, T. M., Currie, D. W., Clark, S., Pogosjans, S., Kay, M., Schwartz, N. G., . . . Team, C. C.-I. (2020). Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med, 382(21), 2005-2011. doi:10.1056/NEJMoa2005412

Miller, J.C., Qiu, X., MacFadden, D., & Hanage, W.P. (2020). Evaluating the contributions of strategies to prevent SARS-CoV-2 transmission in healthcare setting: a modelling study. Preprint medRxiv doi:10.1101/2020.04.20.20073080

Morawska, L., & Milton, D. K. (2020). It is Time to Address Airborne Transmission of COVID-19. Clin Infect Dis 71(9), 2311-2313. doi:10.1093/cid/ciaa939

Morcuende, M., Guglielminotti, J., & Landau, R. (2020). Anesthesiologists' and intensive care providers' exposure to covid-19 infection in a new york city academic center: A prospective cohort study assessing symptoms and covid-19 antibody testing. Anesthesia & Analgesia, 131(3), 669-676. doi:10.1213/ANE.0000000000005056

Mortgat, L., Barbezange, C., Fischer, N., Heyndrickx, L., Hutse, V., Thomas, I., . . . Duysburgh, E. (2020). SARS-CoV-2 prevalence and seroprevalence among healthcare workers in Belgian hospitals: Baseline results of a prospective cohort study. Preprint medRxiv doi:10.1101/2020.10.03.20204545

Mponponsuo, K., Kerkerian, G., Somayaji, R., Missaghi, B., Vayalumkal, J. V., Larios, O. E., . . . Conly, J. (2020). Lack of nosocomial transmission to exposed inpatients and coworkers in an investigation of five SARS-CoV-2-infected healthcare workers. Infect Control Hosp Epidemiol. doi:10.1017/ice.2020.392 Epub ahead of print

Muik, A., Wallisch, A. K., Sanger, B., Swanson, K. A., Muhl, J., Chen, W., . . . Sahin, U. (2021). Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science, 371(6534), 1152-1153. doi:10.1126/science.abg6105

Nasia, S., Gage, K. M., Katarina, M. B., Thomas, C. F., & David, H. O. C. (2020). Determining the source of transmission of SARS-CoV-2 infection in a healthcare worker. Preprint medRxiv doi:10.1101/2020.04.27.20077016

National Collaborating Centre for Methods and Tools. (2020). Rapid Review: What risk factors are associated with COVID-19 outbreaks and mortality in long-term care facilities and what strategies mitigate risk? Retrieved from: https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service/26

Naveca, F., da Costa, C., Nascimento, V., Souza, V., Corado, A., Nascimento, F., &
Resende, P. C. (2021). SARS‐CoV‐2 reinfection by the new variant of concern (VOC) P.1 in Amazonas, Brazil.   Retrieved from https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concernvoc-p-1-in-amazonas-brazil/596

NERVTAG. (2021, January 22, 2021). NERVTAG paper on COVID-19 variant of concern B.1.1.7.  Retrieved from https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of concern-b117

Nishida, T., Iwahashi, H., Yamauchi, K., Kinoshita, N., Okauchi, Y., Suzuki, N., . . . Abe, K. (2020). Seroprevalence of SARS-CoV-2 antibodies among 925 staff members in an urban hospital accepting COVID-19 patients in Osaka prefecture, Japan. Preprint medRxiv doi:10.1101/2020.09.10.20191866

Ong, S. W. X., Tan, Y. K., Chia, P. Y., Lee, T. H., Ng, O. T., Wong, M. S. Y., & Marimuthu, K. (2020). Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. JAMA, 323(16), 1610-1612. doi:10.1001/jama.2020.3227

Ontario Agency for Health Protection and Promotion (Public Health Ontario), Provincial Infectious Diseases Advisory Committee. Interim guidance for infection prevention and control of SARS-CoV-2 variants of concern for health care settings. 1st revision. Toronto, ON: Queen's Printer for Ontario; 2021

Oran, D. P., & Topol, E. J. (2020). Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med, 173(5), 362-367. doi:10.7326/M20-3012

Park, S. Y., Kim, Y. M., Yi, S., Lee, S., Na, B. J., Kim, C. B., . . . Jeong, E. K. (2020). Coronavirus Disease Outbreak in Call Center, South Korea. Emerg Infect Dis, 26(8), 1666-1670. doi:10.3201/eid2608.201274

Pawlowski, C., Lenehan, P., Puranik, V., Venkatakrishnan, A. J., Niewsen, M. J. M., O’’Horo, J. C., & Soundararajan, V. (2021). FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Preprint medRxiv. doi:10.1101/2021.02.15.21251623

Prasitsirikul, W., Pongpirul, K., Pongpirul, W. A., Panitantum, N., Ratnarathon, A. C., & Hemachudha, T. (2020). Nurse infected with COVID-19 from a provisional dengue patient. Emerg Microbes Infect, 9(1), 1354-1355. doi:10.1080/22221751.2020.1775131

Public Health Agency of Canada. (2012). Hand Hygiene Practices in Healthcare Settings. https://www.canada.ca/en/public-health/services/infectious-diseases/nosocomial-occupational-infections/hand-hygiene-practices-healthcare-settings.html

Public Health Agency of Canada. (2013). Routine Practices and Additional Precautions for Preventing the Transmission of Infection in Healthcare Settings. https://www.canada.ca/en/public-health/services/infectious-diseases/nosocomial-occupational-infections/routine-practices-additional-precautions-preventing-transmission-infection-healthcare-settings.htm

Public Health England/National Health Service. (2020). COVID-19: Guidance for the remobilisation of services within health and care settings.   Retrieved from https://www.bsperio.org.uk/news/covid-19-guidance-for-the-remobilisation-of-services-within-health-and-care-settings

Resende, P. C. (2021). Spike E484K Mutation in the First SARS-CoV-2 Reinfection Case Confirmed in Brazil, 2020.   Retrieved from https://virological.org/t/spike-e484k-mutation-in-the-first-sars-cov-2 reinfection-case-confirmed-in-brazil-2020/584

Rickman, H. M., Rampling, T., Shaw, K., Martinez-Garcia, G., Hail, L., Coen, P., . . . Houlihan, C. F. (2020). Nosocomial transmission of COVID-19: A retrospective study of 66 hospital-acquired cases in a London teaching hospital. Clin Infect Dis. doi:10.1093/cid/ciaa816 Epub ahead of print

Sabino, E. C., Buss, L. F., Carvalho, M. P. S., Prete, C. A., Jr., Crispim, M. A. E., Fraiji, N. A., . . . Faria, N. R. (2021). Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet, 397(10273), 452-455. doi:10.1016/S0140-6736(21)00183-5

SARS‐CoV‐2 reinfection by the new variant of concern (VOC) P.1 in Amazonas, Brazil. (2021).  Retrieved from https://virological.org/t/sars-cov-2-reinfection-by-the new-variant-of-concern-voc-p-1-in-amazonas-brazil/596

Stamatatos, L., Czartoski, J., Wan, Y. H., Homad, L. J., Rubin, V., Glantz, H., . . . McGuire, A. T. (2021). mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. doi:10.1126/science.abg9175

Schmitz, D., Vos, M., Stolmeijer, R., Lameijer, H., Schonberger, T., Gaakeer, M. I., . . . Ter Avest, E. (2020). Association between personal protective equipment and SARS-CoV-2 infection risk in emergency department healthcare workers. doi:10.1097/MEJ.0000000000000766 Eur J Emerg Med. Epub ahead of print.

Schwartz, C., Oster, Y., Slama, C., Benenson, S., & Hadassah, C.-I. W. G. (2020). A dynamic response to exposures of health care workers to newly diagnosed COVID-19 patients or hospital personnel, in order to minimize cross-transmission and the need for suspension from work during the outbreak. Open Forum Infect Dis, 7(9), ofaa384. doi:10.1093/ofid/ofaa384

Schwierzeck, V., König, J. C., Kühn, J., Mellmann, A., Correa-Martínez, C. L., Omran, H., . . . Kampmeier, S. (2020). First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. Clin Infect Dis. doi:10.1093/cid/ciaa491 Epub ahead of print.

Seidelman, J. L., Lewis, S. S., Advani, S. D., Akinboyo, I. C., Epling, C., Case, M., . . . Smith, B. A. (2020). Universal masking is an effective strategy to flatten the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) healthcare worker epidemiologic curve. Infect Control Hosp Epidemiol, 1-2. doi:10.1017/ice.2020.313

Shallcross, L., Burke, D., Stat, O. A. C., Donaldson, A., Hallatt, G., Hayward, A., . . . Thorne, S. (2020). Risk factors associated with SARS-CoV-2 infection in outbreaks in Long Term Care Facilities in England: a national survey. Preprint medRxiv doi:10.1101/2020.10.02.20205591

Shen, Y., Li, C., Dong, H., Wang, Z., Martinez, L., Sun, Z., . . . Xu, G. (2020). Community Outbreak Investigation of SARS-CoV-2 Transmission Among Bus Riders in Eastern China. JAMA Intern Med. doi:10.1001/jamainternmed.2020.5225 Epub ahead of print

Sikkema, R. S., Pas, S. D., Nieuwenhuijse, D. F., Toole, Á., Verweij, J., van der Linden, A., . . . Koopmans, M. P. G. (2020). COVID-19 in health-care workers in three hospitals in the south of the Netherlands: A cross-sectional study. Lancet Infect Dis, 20(11), 1273-1280. doi:10.1016/S1473-3099(20)30527-2

Somsen, G. A., van Rijn, C., Kooij, S., Bem, R. A., & Bonn, D. (2020). Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. Lancet Respir Med, 8(7), 658-659. doi:10.1016/S2213-2600(20)30245-9

Stadnytskyi V, Bax CE, Bax A, Anfinrud P. The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. Proc Ntl Acad Sci. 2020;117:11875-7. doi:10.1073/pnas.2006874117

Stone, N. D., Ashraf, M. S., Calder, J., Crnich, C. J., Crossley, K., Drinka, P. J., . . . Society for Healthcare Epidemiology Long-Term Care Special Interest, G. (2012). Surveillance definitions of infections in long-term care facilities: revisiting the McGeer criteria. Infect Control Hosp Epidemiol, 33(10), 965-977. doi:10.1086/667743

Tada, T., Dcosta, B. M., Samanovic-Golden, M., Herati, R. S., Cornelius, A., Mulligan, M. J., & Landau, N. R. (2021). Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. Preprint bioRxiv. doi:10.1101/2021.02.05.430003

Tande, A. J., Pollock, B. D., Shah, N. D., Farrugia, G., Virk, A., Swift, M., . . . Berbari, E. F. (2021). Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening. Clin Infect Dis. doi:10.1093/cid/ciab229

Telford, C. T., Bystrom, C., Fox, T., Wiggins-Benn, S., McCloud, M., Holland, D. P., & Shah, S. (2020). Assessment of Infection prevention and Control Protocols, Procedures, and Implementation in Response to the COVID-19 Pandemic in Twenty-three Long-term Care Facilities in Fulton County, Georgia. Preprint medRxiv preprint doi:10.1101/2020.08.13.20174466

Tran, K., Cimon, K., Severn, M., Pessoa-Silva, C. L., & Conly, J. (2012). Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One, 7(4), e35797. doi:10.1371/journal.pone.0035797

Tubiana, S., Burdet, C., Houhou, N., Thy, M., Manchon, P., Blanquart, F., . . . Duval, X. (2020). High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in healthcare workers: Results of the CoV-CONTACT prospective cohort. Preprint medRxiv doi:10.1101/2020.09.17.20194860

Turcato, G., Zaboli, A., & Pfeifer, N. (2020). The COVID-19 epidemic and reorganisation of triage, an observational study. Inter Emerg Med, 15(8), 1517-1524. doi:10.1007/s11739-020-02465-2

van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., . . . Munster, V. J. (2020). Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med, 382(16), 1564-1567. doi:10.1056/NEJMc2004973

van Kampen, J. J. A., van de Vijver, D. A. M. C., Fraaji, P. L. A., KHaagmans, B. L., Lamers, M. M., Okba, N., . . . van der Eijk, A. A. (2020). Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. Preprint medRxiv doi:10.1101/2020.06.08.20125310

Vaseleiou, E., Simpson, C. R., Robertson, C., Shi, T., Kerr, S., Agrawal, U., & Sheikh, A. (2021). Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. Preprint SSRN. doi:10.2139/ssrn.3789264

Vasques Nonaka, C. K., Miranda Franco, M., Graf, T., Almeida Mendes, A. V., Santana de Aquiar, R., Giiovanetti, M., & Solano de Freitas Souza, B. (2021). Genomic evidence of a SARS-CoV-2 reinfection case with E484K spike mutation in Brazil. Preprint (www.preprints.org). doi: 10.20944/preprints202101.0132.v1

Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O'Toole, A., . . . Connor, T. R. (2021). Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell, 184(1), 64-75 e11. doi:10.1016/j.cell.2020.11.020

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., . . . Oxford, C.V.T.G. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 397(10269), 99-111. doi:10.1016/S0140-6736(20)32661-1

Wake, R. M., Morgan, M., Choi, J., & Winn, S. (2020). Reducing nosocomial transmission of covid-19: Implementation of a covid-19 triage system. Clin Med (Lond), 20(5), e141-e145. doi:10.7861/clinmed.2020-0411

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., . . . Ho, D. D. (2021). Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. Preprint bioRxiv. doi:10.1101/2021.01.25.428137

Wang, Q., Huang, X., Bai, Y., Wang, X., Wang, H., Hu, X., . . . Zhao, H. (2020). Epidemiological characteristics of covid-19 in medical staff members of neurosurgery departments in Hubei province: A multicentre descriptive study. Preprint medRxiv doi:10.1101/2020.04.20.20064899

Wang, X., Ferro, E. G., Zhou, G., Hashimoto, D., & Bhatt, D. L. (2020). Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. JAMA, 324(7), 703-4. doi:10.1001/jama.2020.12897

Wang, Y., Wu, W., Cheng, Z., Tan, X., Yang, Z., Zeng, X., . . . Wang, X. (2020). Super-factors associated with transmission of occupational covid-19 infection among healthcare staff in Wuhan, China. J Hosp Infect, 106(1), 25-34. doi:10.1016/j.jhin.2020.06.023

Wee, L. E. I., Sim, X. Y. J., Conceicao, E. P., Aung, M. K., Tan, K. Y., Ko, K. K. K., . . . Ling, M. L. (2020). Containing covid-19 outside the isolation ward: The impact of an infection control bundle on environmental contamination and transmission in a cohorted general ward. Am J Infect Control, 48(9), 1056-1061. doi:10.1016/j.ajic.2020.06.188

Wee, L. E., Sim, X. Y. J., Conceicao, E. P., Aung, M. K., Goh, J. Q., Yeo, D. W. T., . . . Venkatachalam, I. (2020). Containment of covid-19 cases among healthcare workers: The role of surveillance, early detection, and outbreak management. Infect Control Hosp Epidemiol, 41(7), 765-771. doi:10.1017/ice.2020.219

Wei WE LZ, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23 - March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:411–415. doi:10.15585/mmwr.mm6914e1

WHO. (2020). Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed Interim Guidance 29 June 2020.   Retrieved from https://www.who.int/publications/i/item/WHO-2019-nCoV-IPC-2020.4

WHO. (2021). Infection prevention and control guidance for long-term care facilities in the context of COVID-19: Interim Guidance 8 January 2021.   Retrieved from https://apps.who.int/iris/handle/10665/338481

WHO. (2020). Mask use in the context of COVID-19.   Retrieved from https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak World Health Organization.

WHO. (2020). Transmission of SARS-CoV-2: implications for infection prevention precautions.   Retrieved from https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions

Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., . . . Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. doi:10.1038/s41591-021-01285-x

Wilkins, J., Gray, E. L., Wallia, A., Hirschhorn, L., Zembower, T., Ho, J., . . . Evans, C. (2020). Seroprevalence and correlates of SARS-CoV-2 antibodies in healthcare workers in Chicago. Open Forum Infect Dis. doi:10.1093/ofid/ofaa582 Epub ahead of print.

Wolfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Muller, M. A., . . . Wendtner, C. (2020). Virological assessment of hospitalized patients with COVID-2019. Nature, 581(7809), 465-469. doi:10.1038/s41586-020-2196-x

Wu, K., Werner, A. P., Moliva, J. I., Ko ch, M., Choi, A., Stewart-Jones, G. B. E., . . . Edwards, D. K. (2021). mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS CoV-2 variants. Preprint bioRxiv. doi:10.1101/2021.01.25.427948

Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., . . . Shi, P. Y. (2021). Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. doi:10.1038/s41591-021-01270-4

Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., . . . Dormitzer, P. R., Shi, P-Y. (2021). Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. Preprint bioRxiv. doi:10.1101/2021.01.07.425740

Yu, I. T., Li, Y., Wong, T. W., Tam, W., Chan, A. T., Lee, J. H., . . . Ho, T. (2004). Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med, 350(17), 1731-1739. doi:10.1056/NEJMoa032867

Zhang, W., Davis, B. D., Chen, S. S., Sincuir Martinez, J. M., Plummer, J. T., & Vail, E. (2021). Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA, 325(13), 1324-1326. doi:10.1001/jama.2021.1612

Zheng, C., Hafezi-Bakhtiari, N., Cooper, V., Davidson, H., Habibi, M., Riley, P., & Breathnach, A. (2020). Characteristics and transmission dynamics of COVID-19 in healthcare workers at a London teaching hospital. J Hosp Infect, 106(2), 325-329. doi:10.1016/j.jhin.2020.07.025

Zhong, Q., Liu, Y. Y., Luo, Q., Zou, Y. F., Jiang, H. X., Li, H., . . . Zhang, Z. Z. (2020). Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: Retrospective, single-centre, observational cohort study. Br J Anaesth, 124(6), 670-675. doi:10.1016/j.bja.2020.03.007

Zucman, N., Uhel, F., Descamps, D., Roux, D., & Ricard, J. D. (2021). Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report. Clin Infect Dis. doi:10.1093/cid/ciab129

Page details

Date modified: